Sign InBreakout Stocks of Week 28 @ FRA
NASDAQ was up last week (week 27) by 2.04% ending at 25,813.43 points after gaining 515.81 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Rio Tinto Group FRA:RIO1. This stock has had a buy signal since Jul 03, 2026 when the price was 82.53€ , but have so far fallen 0% to 82.53€. Some other companies are on our watchlist to, among these are which all got a breakout pattern emerging.
| Date | Company | Price | Week 28 |
|---|---|---|---|
| Rio Tinto Group | 82.53€ | 79.38€ | -3.82% |
The Rio Tinto Group stock price gained 0.0728% on the last trading day (Friday, 3rd Jul 2026), rising from 82.47€ to 82.53€. During the last trading day the stock fluctuated 1.25% from a day low at 82.48€ to a day high of 83.51€. The price has been going up and down for this period, and there has been a -3.67% loss for the last 2 weeks. Volume fell on the last day by -10 thousand shares and in total, 26 thousand shares were bought and sold for approximately 2.18€ million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Rio Tinto Group holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Rio Tinto Group:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
FOX
$50.81
|
2.22% | Jul 27 |
UNFI
$49.05
|
3.63% | Jul 27 |
BIIB
$202.19
|
0.376% | Jul 24 |
TSCO
$30.32
|
1.48% | Jul 23 |
|
S
SW
$43.71
|
5.17% | Jul 23 |
